Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290


Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.


A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor.

Dewald G.

Biochem Biophys Res Commun. 2018 Mar 25;498(1):193-198. doi: 10.1016/j.bbrc.2017.12.060.


Patient Care Technicians Managing Hemodialysis Central Venous Catheter Care: Pro and Con.

Bennett PN, Dewald G.

Nephrol Nurs J. 2017 Sep-Oct;44(5):449-454. Review.


Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS; ECOG-ACRIN Cancer Research Group.

Leuk Res. 2017 Aug;59:55-64. doi: 10.1016/j.leukres.2017.05.010. Epub 2017 May 12.


Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR.

Leuk Lymphoma. 2015;56(11):3031-7. doi: 10.3109/10428194.2015.1023800. Epub 2015 Mar 30.


The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.

Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM.

Haematologica. 2013 Jun;98(6):945-52. doi: 10.3324/haematol.2012.081877. Epub 2013 Jan 24.


Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).

Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS.

Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22.


Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?

Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, Haferlach C, Hildebrandt B, Iqbal AM, Jhanwar SC, Ohyashiki K, Sole F, Vandenberghe P, VanDyke DL, Zhang Y, Dewald GW.

Leuk Res. 2012 Jul;36(7):832-40. doi: 10.1016/j.leukres.2012.03.013. Epub 2012 Apr 25.


Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, Litzow MR, Tallman MS.

Blood. 2011 Sep 29;118(13):3525-7. doi: 10.1182/blood-2011-03-342485. Epub 2011 Jul 29.


Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS.

Blood. 2011 May 19;117(20):5306-13. doi: 10.1182/blood-2010-09-309229. Epub 2011 Mar 17.


Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.

Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW.

Cancer Genet Cytogenet. 2010 Dec;203(2):141-8. doi: 10.1016/j.cancergencyto.2010.08.009.


Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease.

Kuijpers TW, Nguyen M, Hopman CT, Nieuwenhuys E, Dewald G, Lankester AC, Roos A, van der Ende A, Fijen C, de Boer M.

Mol Immunol. 2010 Jan;47(4):671-7. doi: 10.1016/j.molimm.2009.10.017. Epub 2009 Nov 22.


T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM.

Blood. 2009 Dec 10;114(25):5136-45. doi: 10.1182/blood-2009-08-231217.


Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.

Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS; Eastern Cooperative Oncology Group Leukemia Committee.

Br J Haematol. 2010 Jan;148(2):217-25. doi: 10.1111/j.1365-2141.2009.07917.x. Epub 2009 Oct 5.


Anthracycline dose intensification in acute myeloid leukemia.

Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.


Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.

Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM.

Mayo Clin Proc. 2009 Sep;84(9):801-10. doi: 10.1016/S0025-6196(11)60490-4.


Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM.

Blood. 2009 Sep 17;114(12):2393-400. doi: 10.1182/blood-2009-03-211797. Epub 2009 Jun 29.


A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26. Erratum in: Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14504.


Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE.

J Clin Oncol. 2009 Apr 10;27(11):1844-9. doi: 10.1200/JCO.2008.17.0795. Epub 2009 Mar 2.


Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.

Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH.

Blood. 2009 May 7;113(19):4489-96. doi: 10.1182/blood-2009-01-199380. Epub 2009 Feb 24.


Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q.

Chen D, Hoyer JD, Ketterling RP, Tefferi A, Steensma DP, Holtan SG, Santana-Davila R, Porrata LF, Dewald GW, Hanson CA.

Leukemia. 2009 Apr;23(4):796-800. doi: 10.1038/leu.2008.279. Epub 2008 Oct 23. No abstract available.


Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.

Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP.

Am J Hematol. 2008 Sep;83(9):708-13. doi: 10.1002/ajh.21245.


Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.

Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA.

Leuk Res. 2008 Dec;32(12):1927-30. doi: 10.1016/j.leukres.2008.04.022. Epub 2008 Jun 9.


Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression.

Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, Jelinek DF, Kay NE.

J Clin Oncol. 2008 May 10;26(14):e5-6. doi: 10.1200/JCO.2008.16.7874. No abstract available.


International Working Group on MDS cytogenetics: October 2007 meeting report.

Slovak ML, Dewald GW; International Working Group on MDS cytogenetics.

Leuk Res. 2008 Sep;32(9):1329-32. doi: 10.1016/j.leukres.2008.03.009.


Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence.

Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC.

Diagn Pathol. 2008 Apr 18;3:16. doi: 10.1186/1746-1596-3-16.


CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE.

Br J Haematol. 2008 Mar;140(5):537-46. doi: 10.1111/j.1365-2141.2007.06965.x.


Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies.

Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Hanson CA, Tefferi A.

Leuk Res. 2008 Oct;32(10):1597-600. doi: 10.1016/j.leukres.2007.12.005. Epub 2008 Feb 1.


Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF.

J Clin Invest. 2008 Jan;118(1):306-15.


Isochromosome (X)(p10) in hematologic disorders: FISH study of 14 new cases show three types of centromere signal patterns.

Adeyinka A, Smoley S, Fink S, Sanchez J, Van Dyke DL, Dewald G.

Cancer Genet Cytogenet. 2007 Nov;179(1):25-30.


Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course.

Bork K, Gül D, Hardt J, Dewald G.

Am J Med. 2007 Nov;120(11):987-92.


Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.

Landstrom AP, Knudson RA, Dewald GW, Ketterling RP, Tefferi A.

Leuk Lymphoma. 2007 Nov;48(11):2137-40.


Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF.

Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.


Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A.

Leuk Res. 2008 Mar;32(3):407-11. Epub 2007 Aug 20.


Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM.

Leuk Res. 2007 Dec;31(12):1737-40. Epub 2007 Jul 19.


Chronic lymphocytic leukemia FISH panel: impact on diagnosis.

Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC.

Am J Clin Pathol. 2007 Aug;128(2):323-32.


Guidance for fluorescence in situ hybridization testing in hematologic disorders.

Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, Rao KW, Rao PN; Association for Molecular Pathology Clinical Practice Committee; American College of Medical Genetics Laboratory Quality Assurance Committee.

J Mol Diagn. 2007 Apr;9(2):134-43.


Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ.

Blood. 2007 Jul 1;110(1):409-17. Epub 2007 Mar 20.


Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q.

Smoley SA, Fink SR, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW.

Cancer Genet Cytogenet. 2007 Mar;173(2):144-9.


Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS.

J Clin Oncol. 2007 Mar 1;25(7):793-8. Epub 2007 Feb 5.


Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC.

J Clin Oncol. 2007 Mar 1;25(7):799-804. Epub 2007 Feb 5.


Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute.

Blood. 2007 Apr 15;109(8):3189-97. Epub 2006 Dec 14.


Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.

Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW.

Leuk Res. 2007 Sep;31(9):1185-9. Epub 2006 Nov 27.


The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, Dewald GW, Kurtin PJ.

Am J Surg Pathol. 2006 Dec;30(12):1546-53.


Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators.

N Engl J Med. 2006 Oct 5;355(14):1456-65.


Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.

Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW.

J Clin Oncol. 2006 Oct 1;24(28):4634-41.


Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC.

Blood. 2007 Jan 15;109(2):405-11. Epub 2006 Sep 28.


Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900).

Vance GH, Kim H, Hicks GA, Cherry AM, Higgins R, Hulshizer RL, Tallman MS, Fernandez HF, Dewald GW.

Leuk Res. 2007 May;31(5):605-9. Epub 2006 Sep 22.


The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH.

Br J Haematol. 2006 Oct;135(2):165-73. Epub 2006 Aug 25.


Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum.

Nelson BP, Treaba D, Goolsby C, Williams S, Dewald G, Gordon L, Peterson LC.

Leuk Lymphoma. 2006 Jul;47(7):1352-9.


Supplemental Content

Loading ...
Support Center